What
Biomedrex has developed an adaptable, reusable method for increasing the efficacy and the safety profile of antiviral drugs against pathogenic viruses such as SARS-CoV-2 and HIV-1 that today cannot be cured. Our CRISPR-based antiviral is currently in the preclinical testing and the company is raising seed for animal studies planned for 2022.
Why
Infectious diseases kill 17 million people yearly. Viruses such as SARS-CoV-2 and HIV cause millions of deaths and huge economical burden. These viruses cannot be cured today. The company’s mission is to develop antivirals curing pathogenic viruses such as SARS-CoV-2 and HIV.
How
The team has developed a reusable discovery platform utilising Nobel-prize winner CRISPR-technology to rapidly design drug candidates against new viruses. Thanks to positive results from the first clinical trial, CRISPR-based medicines have recently gained plenty of attention and are considered as a future of medicines providing cures to many incurable diseases.
Building on proven components
CRISPR: proven to work against virusesFast progress: Eligible for FDA’s acceleration programs
Technology that can be used against any virus
Multidisciplinary team that has done this journey before
Advisory board of strong individuals